Delving into the Latest Updates on Second Hospital of Tianjin Medical University with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Immune System Diseases

Oncolytic virus

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
Oncolytic virus	1

Top 5 Target	Count

Nrf2 x STAT3	1
CD molecules	1

This study aims to evaluate the incidence, clinical characteristics, and short-term prognosis of acute cerebrovascular events occurring in-hospital in patients with arrhythmias following catheter ablation. The goal is to provide evidence supporting the improvement of patient quality of life and reduction of in-hospital acute cerebrovascular complications in patients with post-ablation arrhythmias. This will also contribute to the evidence-based clinical management of such patients.

Start Date15 Jan 2025

Sponsor / Collaborator

The First Affiliated Hospital of Xi'an Jiaotong University

[+4]

NCT06739395

/ RecruitingPhase 2IIT

A Pan-Cancer Basket, Real World, Open-label, Multicenter Study on Molecular Matching Therapy Guided by Molecular Tumor Boards (MTB) for Pan Solid Tumor Patients With Standard Treatment Exhaustion

The main purpose of this study is to explore the feasibility of selecting treatment plans based on genomic variations guided by MTB in patients with advanced refractory solid tumors.

Start Date01 Nov 2024

Sponsor / Collaborator

Second Hospital of Tianjin Medical University

ChiCTR2400091033

/ SuspendedEarly Phase 1IIT

Research on the Effect of Chicory Compound Dietary Fiber on Improving Functional Constipation

Start Date20 Oct 2024

Sponsor / Collaborator

Second Hospital of Tianjin Medical University

100 Clinical Results associated with Second Hospital of Tianjin Medical University

Login to view more data

0 Patents (Medical) associated with Second Hospital of Tianjin Medical University

Login to view more data

2,057

Literatures (Medical) associated with Second Hospital of Tianjin Medical University

31 Dec 2025·Annals of Medicine

Utilizing vaginal natural orifice to facilitate bowel manipulation during totally intracorporeal ileal conduit construction: a retrospective cohort study

Author: Huang, Shiwang ; Lin, Yuda ; Qie, Yunkai ; Wu, Zhouliang ; Zhang, Zhe ; Wang, Zhun ; Shen, Chong ; Bai, Yiduo ; Jia, Kaipeng ; Hu, Hailong

01 Dec 2025·Functional & Integrative Genomics

Transcription factor MAZ activates the transcription of hypomethylated TYMP in ccRCC

Article

Author: Wang, Yong ; Dong, Yihan ; Li, Jiaxin ; Wang, Rui ; Yue, Dan ; Jiang, Huamao ; Liu, Xinyu ; Lin, Tianyu

Clear cell renal cell carcinoma (ccRCC) is a highly malignant tumor characterized by a significant propensity for recurrence and metastasis. DNA methylation has emerged as a critical epigenetic mechanism with substantial utility in cancer diagnosis. In this study, multi-omics data were utilized to investigate the target genes regulated by the transcription factor MYC-associated zinc finger protein (MAZ) in ccRCC, leading to the identification of thymidine phosphorylase (TYMP) as a gene with notably elevated expression in ccRCC. The interaction between MAZ and TYMP was confirmed through chromatin immunoprecipitation (ChIP) assays and bioinformatics analysis. It was found that the binding of MAZ to the TYMP promoter is associated with the methylation status of this promoter region. Furthermore, the methylation of the TYMP promoter appears to be correlated with both the clinicopathological stage and overall survival of ccRCC patients. Further exploration of genes within the "nucleotide metabolism" pathway, identified through Gene Ontology (GO) enrichment analysis, revealed that uridine phosphorylase 1 (UPP1) interacts with TYMP. Interestingly, UPP1 was also shown to be activated by MAZ, suggesting a coordinated regulatory mechanism. Based on these findings, we propose that the TYMP-UPP1 complex, co-regulated by MAZ, plays a pivotal role in nucleotide metabolism in ccRCC. These results suggest that TYMP may contribute to the pathophysiology of ccRCC and that promoter methylation offers potential as a prognostic indicator, providing novel insights into the molecular underpinnings of ccRCC and potential avenues for therapeutic intervention.

01 Apr 2025·American Heart Journal

Indobufen-based dual antiplatelet therapy in patients with multivessel coronary disease undergoing drug-eluting stent implantation insight from the OPTION trial

Article

Author: Wu, Hongyi ; Qian, Juying ; Wu, Shujing ; Wei, Guanghe ; Xu, Huajie ; Huang, Jiangnan ; Chen, Manhua ; Li, Guangping ; Lan, Jun ; Xu, Lili ; Zhao, Xin ; Wang, Xiaoyan ; Zhang, Huanyi ; Ge, Junbo ; Qi, Zhiyong ; Cheng, Kang

BACKGROUNDIt remains unclear whether indobufen-based dual antiplatelet therapy (DAPT) preserves ischemic protection while limiting bleeding risk in patients with multivessel coronary disease (MVD). This study aimed to investigate the efficacy and safety of indobufen-based DAPT in patients with MVD.METHODSPatients in the OPTION trial were stratified based on the presence of MVD. We compared the ischemic and bleeding risks of indobufen-based DAPT (indobufen 100mg twice a day plus clopidogrel 75 mg/d for 12 months) vs conventional DAPT (aspirin 100 mg/d plus clopidogrel 75 mg/d for 12 months) in patients with and without MVD, using landmarks at 6 months and 1-year post-percutaneous coronary intervention (PCI).RESULTSPatients with MVD tended to be older and contained a higher prevalence of high-risk features. Compared with patients without MVD, those with MVD were at higher risk for net adverse clinical events and ischemic events. The risk of ischemic events between indobufen-based DAPT vs conventional DAPT was similar either in patients with MVD or without MVD during the first and second 6 months. During the first 6 months, indobufen-based DAPT decreased the risk of bleeding events consistently in patients with and without MVD. Of note, during the second 6 months, indobufen-based DAPT continually decreased the risk of bleeding events in patients with MVD but not in those without MVD.CONCLUSIONSIn patients with MVD, indobufen plus clopidogrel DAPT compared to aspirin plus clopidogrel DAPT could reduce the risk of bleeding events while preserving ischemic protection during both the first and second 6 months post-PCI. Indobufen presents an effective option for patients with MVD, especially those at high ischemic risk requiring DAPT beyond 6 months post-PCI.TRIAL REGISTRATIONThe trial was registered at www.chictr.org. A Randomized Controlled Trial of Indobufen vs Aspirin after Coronary Drug-eluting Stent Implantation: the OPTION Trial (ChiCTR-IIR-17013505).

100 Deals associated with Second Hospital of Tianjin Medical University

Login to view more data

100 Translational Medicine associated with Second Hospital of Tianjin Medical University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Login to view more data